Palvella Therapeutics (PVLA) Return on Capital Employed (2014 - 2026)
Palvella Therapeutics (PVLA) reported Return on Capital Employed of 10.32% for Q1 2026, up 1667.0% year-over-year from 0.58% in Q1 2025, and up 38.85% on a QoQ basis from 16.88% in Q4 2025.
Palvella Therapeutics (PVLA) has 13 years of Return on Capital Employed data on file, last reported at 10.32% in Q1 2026.
- Quarterly Return on Capital Employed rose 1667.0% year-over-year to 10.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.32% (up 1667.0% YoY) and the FY2025 annual result came in at 14.0%, up 2531.0% from the prior year.
- Return on Capital Employed climbed to 10.32% in Q1 2026 per PVLA's latest filing, from 16.88% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 19.73% in Q3 2024 and bottomed at 103.19% in Q1 2023.
- The 5-year median for Return on Capital Employed is 38.9% (2023), against an average of 38.95%.
- The widest annual swing landed in 2024, when Return on Capital Employed surged 12032 bps; it then plunged 7248 bps in 2025.
- Tracing PVLA's Return on Capital Employed over 5 years: stood at 58.67% in 2022, then soared by 35 bps to 38.16% in 2023, then increased by 13 bps to 33.29% in 2024, then soared by 49 bps to 16.88% in 2025, then soared by 39 bps to 10.32% in 2026.
- Per Business Quant, the three latest PVLA Return on Capital Employed figures stand at 10.32% (Q1 2026), 16.88% (Q4 2025), and 52.75% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -10.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.32% |
| Dec 31, 2025 | -16.88% |
| Sep 30, 2025 | -52.75% |
| Jun 30, 2025 | -39.64% |
| Mar 31, 2025 | -27.00% |
| Dec 31, 2024 | -33.29% |
| Sep 30, 2024 | 19.73% |
| Jun 30, 2024 | -14.76% |
| Mar 31, 2024 | 17.13% |
| Dec 31, 2023 | -38.16% |
| Sep 30, 2023 | -83.92% |
| Jun 30, 2023 | -75.09% |
| Mar 31, 2023 | -103.19% |
| Sep 30, 2022 | -58.67% |
| Jun 30, 2022 | -55.23% |
| Mar 31, 2022 | -51.23% |
| Dec 31, 2021 | -47.85% |
| Sep 30, 2021 | -48.44% |
| Jun 30, 2021 | -51.63% |
| Mar 31, 2021 | -43.83% |
| Dec 31, 2020 | -38.45% |
| Sep 30, 2020 | -23.53% |
| Jun 30, 2020 | -12.44% |
| Mar 31, 2020 | -18.16% |
| Dec 31, 2019 | -26.65% |
| Sep 30, 2019 | -45.83% |
| Jun 30, 2019 | -48.17% |
| Mar 31, 2019 | -35.11% |
| Dec 31, 2018 | -31.32% |
| Sep 30, 2018 | -10.06% |
| Jun 30, 2018 | -7.87% |
| Mar 31, 2018 | -17.57% |
| Dec 31, 2017 | -26.25% |
| Sep 30, 2017 | -43.37% |
| Jun 30, 2017 | -59.18% |
| Mar 31, 2017 | -71.26% |
| Dec 31, 2016 | -73.40% |
| Sep 30, 2016 | -53.85% |
| Jun 30, 2016 | -46.94% |
| Mar 31, 2016 | -49.38% |
| Dec 31, 2015 | -42.39% |
| Sep 30, 2015 | -56.10% |
| Jun 30, 2015 | -93.99% |
| Mar 31, 2015 | -52.64% |
| Sep 30, 2014 | -339,834.92% |
| Jun 30, 2014 | -75,921.24% |